Nagi S. El-Saghir

Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial

Debu Tripathy, Seock‐Ah Im, Marco Colleoni et al. · The Lancet Oncology · 2018 · 1K citations

Medicine, Oncology, Pharmacology +16

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)

Thomas Bachelot, Eva Ciruelos, Fabio Puglisi et al. · Annals of Oncology · 2019 · 113 citations · Full text

Medicine, Oncology, Pharmacology +17

Cancer incidence in postwar Lebanon: findings from the first national population-based registry, 1998

Ali Shamseddine, Abla Mehio Sibai, Nageeb Gehchan et al. · Annals of Epidemiology · 2004 · 64 citations

Medicine, Health Sciences, Oncology +16

Ratio Between Positive Lymph Nodes and Total Excised Axillary Lymph Nodes as an Independent Prognostic Factor for Overall Survival in Patients with Nonmetastatic Lymph Node-Positive Breast Cancer

Hassan Hatoum, Faek R. Jamali, Nagi S. El-Saghir et al. · Annals of Surgical Oncology · 2009 · 45 citations

Medicine, Oncology, Pathology +15

Abstract PD2-04: Updated overall survival (OS) results from the phase III MONALEESA-7 trial of pre- or perimenopausal patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib

Debu Tripathy, Seock‐Ah Im, Marco Colleoni et al. · Cancer Research · 2021 · 30 citations

Medicine, Oncology, Pharmacology +14